Moderna, Inc. (MRNA) financial statements (2021 and earlier)

Company profile

Business Address 200 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,6081,1031,521
Cash and cash equivalents2,624236658
Short-term investments1,984867863
Restricted cash and investments111
Receivables1,4001220
Inventory, net of allowances, customer advances and progress billings47  
Inventory47  
Prepaid expense16810
Other undisclosed current assets227410
Total current assets:6,2981,1291,563
Noncurrent Assets
Finance lease, right-of-use asset5510
Operating lease, right-of-use asset9086
Property, plant and equipment  212
Long-term investments and receivables639160173
Long-term investments639160173
Restricted cash and investments111112
Other noncurrent assets223
Other undisclosed noncurrent assets242192 
Total noncurrent assets:1,039461399
TOTAL ASSETS:7,3371,5891,962
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities48875110
Accounts payable18731
Accrued liabilities4706879
Deferred revenue3,86763
Other liabilities3453
Other undisclosed current liabilities  109
Total current liabilities:4,389143223
Noncurrent Liabilities
Long-term debt and lease obligation207132 
Finance lease, liability11039
Operating lease, liability9794
Liabilities, other than long-term debt17913910
Deferred revenue177139
Deferred rent credit  10
Other liabilities200
Other undisclosed noncurrent liabilities  199
Total noncurrent liabilities:387271209
Total liabilities:4,775415432
Stockholders' equity
Stockholders' equity attributable to parent2,5611,1751,530
Common stock000
Additional paid in capital4,8022,6692,538
Accumulated other comprehensive income (loss)32(1)
Accumulated deficit(2,244)(1,496)(1,007)
Total stockholders' equity:2,5611,1751,530
TOTAL LIABILITIES AND EQUITY:7,3371,5891,962

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues80360135
Cost of revenue
(Cost of Goods and Services Sold)
(8)  
Gross profit:79560135
Operating expenses(1,559)(606)(548)
Operating loss:(763)(546)(413)
Nonoperating income193129
Investment income, nonoperating253927
Other nonoperating income (expense)(6)(8)2
Interest and debt expense(10)(7) 
Other undisclosed income from continuing operations before equity method investments, income taxes107 
Loss from continuing operations before income taxes:(745)(515)(384)
Income tax expense (benefit)(3)1(0)
Net loss attributable to parent:(747)(514)(385)
Preferred stock dividends and other adjustments  (17)
Net loss available to common stockholders, diluted:(747)(514)(402)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(747)(514)(385)
Comprehensive loss:(747)(514)(385)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent13(0)
Comprehensive loss, net of tax, attributable to parent:(746)(511)(385)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: